ClinicaliQ Trial Snapshot
- A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer’s Disease (ADEPT-5) — Recruiting • Phase III • Neurology • NCT06947941.
- Treatment being tested: KarXT + KarX-EC combination therapy, a novel muscarinic M1/M4 receptor agonist approach, being evaluated specifically for psychosis symptoms in Alzheimer's disease patients.
- Patient eligibility overview: Study recruits individuals with Alzheimer's disease who are experiencing psychotic symptoms (such as hallucinations or delusions), meeting diagnostic criteria for both conditions.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
Eligibility Snapshot
- : * Participants must be 55 to 90 years of age, inclusive, at the time of Screening (Visit 1). * Participants must be diagnosed with Alzheimer's disease in accordance with the 2024 revised criteria for diagnosis and staging of Alzheimer's Disease: Alzheimer's Association Workgroup. * Participants must have a magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain (completed within the past 5 years) taken during or subsequent to the onset of dementia to rule out other central nervous system (CNS) disease that could account for the dementia syndrome, eg, major stroke, neoplasm, subdural hematoma. * Participants must have a history of psychotic symptoms (meeting International Psychogeriatric Association criteria) for at least 2 months prior to Screening (Visit 1) (participants may or may not have symptoms of agitation).
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.